STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Akebia Therapeutics (Nasdaq: AKBA) announced its upcoming participation at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25) in Boston from April 10-13, 2025. The company will present two research posters:

1. A study on cardiovascular risk in patients with DD-CKD comparing Vadadustat vs Darbepoetin Alfa (Poster: G-284)

2. Research on Vadadustat's treatment of anemia comparing older vs younger patients with Dialysis-Dependent-CKD (Poster: G-285)

Dr. Wolfgang Winkelmayer will present the latter study during an oral presentation on April 10, 2025, at 4:00 pm. Attendees can visit Akebia at Booth #1121 in the Exhibit Hall.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the National Kidney Foundation Spring Clinical Meetings 2025 (NKF SCM25), which will take place in Boston, MA from April 10-13, 2025.

Akebia-supported posters will be displayed at NKF SCM25 during Exhibit Hall hours.

  • Cardiovascular Risk in Patients With DD-CKD Randomized to Vadadustat vs Darbepoetin Alfa With or Without Cardiovascular Disease: Poster: G-284

  • Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD: Poster: G-285

On Thursday, April 10, 2025 at 4:00 pm during Oral Poster Presentation: Research 3 at NKF SCM25, Dr. Wolfgang Winkelmayer will present a poster titled “Vadadustat for Treatment of Anemia in Older vs Younger Patients With Dialysis-Dependent-CKD.”

NKF SCM25 attendees can also visit Akebia at Booth #1121 in the Exhibit Hall.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com


FAQ

What research will Akebia Therapeutics (AKBA) present at NKF Spring Clinical Meetings 2025?

Akebia will present two posters: one comparing cardiovascular risk with Vadadustat vs Darbepoetin Alfa, and another studying Vadadustat's effectiveness in different age groups with DD-CKD.

When and where will Akebia Therapeutics (AKBA) present at NKF SCM25?

The presentations will take place at the NKF Spring Clinical Meetings in Boston, MA from April 10-13, 2025, with Dr. Winkelmayer's oral presentation scheduled for April 10 at 4:00 pm.

What are the poster numbers for AKBA's presentations at NKF SCM25?

The posters are G-284 (cardiovascular risk study) and G-285 (age-based Vadadustat treatment study).

Where can attendees find Akebia Therapeutics (AKBA) at NKF SCM25?

Attendees can visit Akebia at Booth #1121 in the Exhibit Hall.
Akebia Therapeut

NASDAQ:AKBA

AKBA Rankings

AKBA Latest News

AKBA Latest SEC Filings

AKBA Stock Data

411.32M
250.09M
3.56%
43.24%
10.22%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
CAMBRIDGE